Can prednisone be used to treat shingles (herpes zoster)?

Prednisone Should Not Be Used as Standard Treatment for Shingles

Prednisone is not recommended for the treatment of herpes zoster (shingles), as it does not prevent postherpetic neuralgia and may increase infection risks, while high-dose IV acyclovir remains the treatment of choice. 1, 2

Primary Treatment Approach

• High-dose IV acyclovir is the treatment of choice for herpes zoster, particularly in immunocompromised patients 1
• Oral antivirals (acyclovir, famciclovir, valacyclovir) should be reserved for mild cases in patients with transient immunosuppression or to complete therapy after clinical response to IV treatment 1
• Antiviral therapy should be initiated within 72 hours of rash onset for maximum benefit 3

Why Prednisone Is Not Recommended

Lack of Efficacy for Preventing Postherpetic Neuralgia

• The most recent Cochrane systematic review (2023) found that corticosteroids given orally during acute herpes zoster infection have uncertain effects on preventing postherpetic neuralgia at 6 months (RR 0.95% CI 0.45-1.99; very low-certainty evidence) 4
• A well-designed 1987 randomized controlled trial demonstrated that prednisolone does not prevent post-herpetic neuralgia, with 24.3% of prednisolone-treated patients developing PHN versus 22.5% in the placebo group at 6 months 5
• A 1994 trial of 400 patients found no significant differences between treatment groups in time to first or complete cessation of pain, with no reduction in postherpetic neuralgia frequency 6

Significant Safety Concerns

The FDA drug label explicitly warns that corticosteroids, including prednisone:

• Suppress the immune system and increase risk of infection with any pathogen 2
• Can exacerbate existing infections and increase risk of disseminated infections 2
• May cause varicella zoster to have a serious or even fatal course in non-immune patients 2
• Can mask signs of infection, making clinical monitoring more difficult 2

Minimal Clinical Benefit

• While some studies showed prednisone provided statistically significant improvement in acute pain during the first 3-7 days, whether these improvements are clinically significant is uncertain 7, 5
• A 1996 trial found that combined acyclovir plus prednisone accelerated healing and return to daily activities, but did not reduce pain at 6 months 8
• The slight benefit for initial symptoms must be weighed against the risk of corticosteroid-related complications 7

Special Circumstances Where Steroids May Be Considered

Herpes Zoster Ophthalmicus-Related Ophthalmoplegia

• A 2021 meta-analysis of 50 cases suggested that extended steroid taper may aid recovery of ophthalmoplegia specifically in HZO (hazard ratio 1.1, P=0.04), though this represents lower-quality case report evidence 9
• This is a specialized indication requiring ophthalmologic consultation and should not be extrapolated to general shingles treatment 9

Middle-Dose Prednisone for Acute Symptom Relief

• A 2019 study found middle-dose prednisone (tapered from 60mg to 15mg over 21 days) shortened pain relief time compared to low or high doses, with similar efficacy but lower complications than high-dose 10
• However, this benefit was only for acute symptoms and did not prevent long-term complications 10

Clinical Pitfalls to Avoid

• Do not use prednisone as a substitute for antiviral therapy - antivirals remain the cornerstone of treatment 1
• Do not assume that reducing acute pain with steroids will prevent postherpetic neuralgia - the evidence clearly shows it does not 5, 4
• Be particularly cautious in immunocompromised patients, where corticosteroids can lead to disseminated VZV infection 1, 2
• The 1-2 week interval between acute treatment and reappearance of pain represents the critical period for neuralgia establishment, which steroids do not prevent 5

Recommended Approach

• Initiate high-dose IV acyclovir (or appropriate oral antiviral for immunocompetent patients with mild disease) within 72 hours of rash onset 1, 3
• For patients at high risk of postherpetic neuralgia, consider early initiation of anticonvulsants or tricyclic antidepressants rather than corticosteroids 3
• Reserve corticosteroid consideration only for specific complications like HZO-related ophthalmoplegia, and only in consultation with appropriate specialists 9
• Monitor for infectious complications if corticosteroids are used, and consider dose reduction or withdrawal if infections develop 2